HOME >> MEDICINE >> NEWS
SKCC's Gennadi Glinsky addresses predicting risk in cancer treatment outcome

-up a clinical trial to evaluate the utility of a genetic test measuring the expression profiles of the 11-gene signature as a prognostic and therapy outcome marker.

Gennadi Victor Glinsky, M.D., Ph.D.

Gennadi Victor Glinsky, M.D., Ph.D., is an associate professor at the Sidney Kimmel Cancer Center in San Diego. He is also a consultant for the National Institutes of Health and serves on the National Cancer Institute Review Panels.

Dr. Glinsky holds membership to numerous professional organizations such as the American Association for the Advancement of Science, the American Association for Cancer Research and the Metastasis Research Society. Dr. Glinsky serves as a reviewer for various journals including the Lancet, Journal of Clinical Investigation, Cancer Research, American Journal of Pathology and Oncogene.

Dr. Glinsky earned a doctor of medicine in internal medicine and general pathology. He later received his doctorate in experimental oncology and biochemistry from the Institute of Oncology Problems Academy of Sciences of Ukraine in Kiev.


'"/>

Contact: Jay Jeffcoat
jjeffcoat@skccfoundation.org
858-410-4212
Sidney Kimmel Cancer Center
18-Apr-2005


Page: 1 2

Related medicine news :

1. Asia-European collaboration addresses water management in Indonesia
2. New technology addresses female fertility preservation
3. New research addresses taboos around the impact of rheumatoid arthritis on patients sex lives
4. Friedman addresses UN-sponsored African workshop on E-Governance
5. New handbook addresses lesbian, gay, bisexual and transgender health issues
6. UK addresses funding gap created by US anti-abortion stance
7. New pediatrician workforce policy addresses growing challenges in health care
8. Child magazine editor addresses regions first annual womens and childrens health care conference
9. Why predicting the next influenza pandemic is difficult and how scientists can best prepare
10. Repeat bone mineral density scans do not appear helpful for predicting fractures in most older women
11. HIV measurement appears to be less reliable than thought in predicting loss of CD4 cells

Post Your Comments:
(Date:4/14/2014)... been made in chemotherapy over the past decade, but ... continues to be a major challenge. , Nanotechnology ... the use of nanocarriers, or capsules, that can transport ... body. , The catch? These carriers are tiny, and ...
(Date:4/14/2014)... the 20th century, is currently losing a lot of ... at the University of South Carolina have just reported ... against so-called "superbugs." , Bacteria have been chipping away ... since their first wide-scale use as antibiotics in the ...
(Date:4/14/2014)... web information on colorectal cancer is too difficult for ... appropriate risks to and concerns of patients, a study ... a review of a dozen popular websites, most of ... were written beyond the recommended sixth-grade reading level, while ...
(Date:4/14/2014)... Inc., announced today a publication demonstrating that the company,s ... cells exposed to plasma samples of patients with a ... "TNT003, an inhibitor of the serine protease C1s, prevents ... was published on-line in the journal Blood ...
(Date:4/14/2014)... Child Development Institute have released their new study of ... success in kindergarten. According to FPG,s report, students enrolled ... of learning. , "Children are progressing at an ... than expected for normal developmental growth," said senior scientist ...
Breaking Medicine News(10 mins):Health News:Nano shake-up 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 3Health News:Website information on colon cancer too complex, fails to address key concerns 2Health News:Website information on colon cancer too complex, fails to address key concerns 3Health News:Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease 2Health News:Study gives high marks to NC Pre-K program 2
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
Cached News: